





**Figure 1.** Sural nerve specimen: A noncaseating granuloma (arrow head) with giant cell, epithelioid histiocyte, and lymphocyte is found in the perineurium (H&E staining; A;  $\times 100$ , B;  $\times 200$ ).

Grade IV, Grade III+ 가

(CIDP) 가

F- 가

3,4 가

(Table 1). 가(66 mm/hr)가

(11.1 g/dL) (11.6 mg/dL) (9.6 mg/dL), (2.6 g/dL)

angiotensin converting enzyme (ACE) 가, (ESR) 가

가 (188.3 U/L), 24 urine, angiotensin converting enzyme(ACE) 가

1-8

(MRI) (CSF), angiotensin converting enzyme(ACE) 가 50~75% 가

2,5,6,8

1, (perineural noncaseating granuloma) (Fig. 1). 가 1,3,5

(axonal degeneration) 5~10%

2,3,4,5

(prednisolone 60 mg) 가 가

**Table 1.** Nerve conduction study

Nerve and Site	Distal motor Latency (msec)	CMAP/SNAP Amplitude (mV/uV)	Conduction Velocity (meter/sec)	F-wave latency (msec)
<b>Motor nerve conduction</b>				
Median nerve (R)				
APB-Wrist	<u>3.7</u>	11.8		<u>32.0</u>
Wrist-Elbow		11.0	<b>38</b>	
Elbow-Axilla		11.0	<b>55.8</b>	
Ulnar nerve (R)				
ADQ-Wrist	<u>2.9</u>	<b>8.9</b>		<u>33.4</u>
Wrist-Elbow		<b>8.0</b>	<b>47</b>	
Elbow-Axilla		<b>8.0</b>	<b>48</b>	
Peroneal nerve (R)				
BFH-EDB		<b>NP</b>		<u>NP</u>
AFH-BFH		<b>NP</b>		
Posterior Tibial nerve (R)				
Ankle-AHB		<b>NP</b>		<u>NP</u>
Politeal fossa-Ankle		<b>NP</b>		
<b>Sensory Nerve conduction</b>				
Median nerve (R)				
Index Finger-Wrist		<b>NP</b>		
Ulnar nerve (R)				
Little Finger-Wrist		<b>NP</b>		
Sural nerve (R/L)				
Laterla Malleolus-Leg		<b>NP / NP</b>		

CMAP, compound muscle action potential; SNAP, sensory nerve action potential; NP, no potential; APB, abductor policis brevis; ADQ, abductor digiti quinti; BFH, below fibular head; AFH, above fibular head; EDB, extensor digitorum brevis; AHB, abductor hallucis brevis. Values below lower normal limit was indicated **bold**, while those above upper normal limit underlined

(CIDP) 가 POEMS ,  
chloroquine 가 hydrochloroquine 가  
methotrexate, azathioprine, cyclosporine 가 .<sup>2,5</sup>

**REFERENCES**

1. Said G. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: A clinicopathological study of 11

patients. *Brain* 2002;125:264-275.  
2. Sharma OP. Neurosarcoidosis: A personal perspective based on the study of 37 patients. *Chest* 1997; 112: 220-228.  
3. Nemni R, Galassi G, Cohen M et al. Symmetric sarcoid polyneuropathy: analysis of a sural nerve biopsy. *Neurology* 1981; 31: 1217-1223.  
4. Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. *Neurology* 1991; 41: 1558-1561.  
5. Chapelon C, Ziza JM, Piette JC et al. Neurosarcoidosis: sign, course, and treatment in 35 confirmed cases. *Medicine* 1990; 69: 261-276.  
6. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. *Arch Neurol* 1985; 42: 909-917.  
7. Sharma OP. Pulmonary sarcoidosis and corticosteroids. *Am Rev Respir Dis* 1993; 147:1598-1600.  
8. Mana J, Salazar A. Neurosarcoidosis: a report of 14 cases. *Sarcoidosis* 1994; 11(supple 1):371-374.  
9. G. zuniga, AH Ropper, and J Frank. Sarcoid peripheral neuropathy. *Neurology* 1991;41: 1558-1561.  
10. Costabel U. Sarcoidosis:clinical update. *Eur Respir J* 2001;32 (Suppl):56-68.